Genetic polymorphisms in SLC5A2 are associated with clinical outcomes and dapagliflozin response in heart failure patients

Genetic polymorphisms in SLC5A2 are associated with clinical outcomes and dapagliflozin response in heart failure patients

BackgroundSodium-glucose cotransporter-2 inhibitors (SGLT2i) have emerged as promising therapeutics for heart failure (HF). Nevertheless, evidence supporting the mechanism of SGLT2i efficacy in HF patients is currently limited. Genetic variation in SLC5A2 (encoding SGLT2) may influence HF progressio...

Full description

Saved in:
Bibliographic Details
Main Authors: Ahmed Essam Abou Warda, Rylie M. Flohr, Rania M. Sarhan, Mohamed Nabil Salem, Heba F. Salem, Ayman N. Moharram, Abdullah S. Alanazi, Christelle Lteif, Brian E. Gawronski, Leanne Dumeny, Tariq G. Alsahli, Khaled Elenizi, Bassem Zarif, Neven Sarhan, Julio D. Duarte
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-04-01
Series:Frontiers in Pharmacology
Subjects:
sodium-glucose transporter 2 inhibitors
heart failure
gene-drug interactions
dapagliflozin
single nuceotide polymorphism
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2025.1539870/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2025.1539870/full

Similar Items